Product image of Linatra (Linagliptin) supplied by GNH India

Linatra

Active Ingredient:
Linagliptin
Origin:
EU

Linatra (Linagliptin)

Linagliptin, the active ingredient in Linatra, is a DPP-4 inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adults.

GNH India supplies Linatra as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing for patients and healthcare providers across multiple regions.

Manufacturer / TM Owner

Zaklady Farmaceutyczne Polpharma S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Linagliptin acts on the incretin pathway to improve glycemic control in type 2 diabetes mellitus.

  • Type 2 diabetes mellitus (monotherapy): improves glycemic control as a single agent.
  • Type 2 diabetes mellitus (combination therapy): used with metformin or other antidiabetics to enhance glucose control.
  • Type 2 diabetes mellitus (renal impairment): provides effective glycemic control without dose adjustment in patients with renal impairment.

How It Works

  • Linagliptin selectively inhibits the dipeptidyl peptidase‑4 (DPP‑4) enzyme, preventing the breakdown of incretin hormones GLP‑1 and GIP. Elevated incretin levels enhance glucose‑dependent insulin secretion, suppress glucagon release, and improve post‑prandial glucose regulation, thereby lowering blood glucose concentrations in patients with type 2 diabetes.

Side Effects

Common Side Effects

  • Nasopharyngitis: mild upper respiratory tract infection.
  • Headache: transient mild to moderate headache.
  • Upper respiratory infection: symptoms of cough and sore throat.
  • Dizziness: occasional light‑headedness.
  • Gastrointestinal discomfort: nausea or abdominal pain.

Serious or Rare Side Effects

  • Pancreatitis: severe abdominal pain requiring immediate medical attention.
  • Severe hypersensitivity reactions: rash, angioedema, or anaphylaxis.
  • Hepatic injury: elevated liver enzymes or jaundice.
  • Bullous pemphigoid: blistering skin disorder.
  • Severe allergic reactions: urticaria or bronchospasm.

Precautions & Warnings

Linagliptin should be used with caution in specific patient populations and clinical situations.

  • Renal function: no dose adjustment required, but monitor renal status regularly.
  • Hepatic impairment: use with caution and monitor liver function tests.
  • Hypersensitivity: discontinue immediately if allergic reactions occur.
  • Pregnancy: safety not established; avoid unless benefit outweighs potential risk.
  • Elderly patients: monitor for adverse reactions due to possible comorbidities.
  • Store at ambient temperature: keep in the original packaging, protect from moisture and light.

Avoid Interactions

Linagliptin may interact with several medicines that affect its plasma concentration or pharmacodynamic response.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors: may increase linagliptin exposure and risk of side effects.
  • Strong CYP3A4 inducers: may reduce linagliptin effectiveness.
  • Insulin secretagogues (e.g., sulfonylureas): increased risk of hypoglycemia.

Moderate Interactions (Monitor Closely)

  • Diuretics: may diminish antihyperglycemic effect of linagliptin.
  • Rifampin: can lower linagliptin plasma levels, reducing efficacy.

Frequently Asked Questions

Linatra contains linagliptin, a DPP‑4 inhibitor prescribed to improve blood glucose control in adults with type 2 diabetes mellitus, either as monotherapy or in combination with other antidiabetic agents.

Linagliptin selectively blocks the DPP‑4 enzyme, which normally degrades the incretin hormones GLP‑1 and GIP. By preserving these hormones, it enhances glucose‑dependent insulin release, reduces glucagon secretion, and helps lower post‑prandial blood glucose levels.

The prescribed dose of Linatra is determined by the treating physician based on the individual’s clinical condition, renal and hepatic function, and concomitant therapies. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety of linagliptin in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the Linatra product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Linagliptin differs from many other DPP‑4 inhibitors because it does not require dose adjustment in renal impairment, owing to its primarily non‑renal elimination. Efficacy and safety profiles are comparable, but the lack of renal dosing changes can simplify treatment in patients with reduced kidney function.

Linatra should be stored at ambient temperature, below 25 °C, in its original container. Protect the product from moisture, excessive heat and direct sunlight to maintain its stability throughout its shelf life.

Linatra is taken orally, usually once daily, with or without food, as directed by the prescribing clinician. The tablet should be swallowed whole with water and not crushed or chewed unless specifically instructed.

Serious risks include pancreatitis, severe hypersensitivity reactions such as anaphylaxis, and rare skin disorders like bullous pemphigoid. Patients should seek immediate medical attention if they experience persistent abdominal pain, rash, swelling, or breathing difficulties.

Linatra is contraindicated in individuals with known hypersensitivity to linagliptin or any component of the formulation. Caution is also advised for patients with a history of pancreatitis or severe hepatic disease, and it should be avoided in pregnancy unless clearly indicated by a physician.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Linagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT